Alzumab 25mg Injection

Alzumab 25mg Injection is a monoclonal antibody that helps regulate immune system activity. It is used in the treatment of moderate to severe plaque psoriasis that requires systemic therapy, as well as for treating cytokine release syndrome associated with moderate to severe COVID-19-related ARDS. Alzumab 25mg Injection is given by intravenous infusion by a doctor or a nurse in a hospital or clinical setting. It is infused slowly over several hours. It is important to attend every scheduled dose and monitoring appointment since treatment response and safety are closely observed. The treatment schedule should be followed exactly as directed by the doctor. Some people may experience infusion-related reactions during or after receiving Alzumab 25mg Injection, such as chills, fever, rash, cough, breathing difficulty, flushing, headache, or changes in blood pressure. These are more common during the first infusion and usually improve with slower administration and appropriate management. Alzumab 25mg Injection should not be used in people who have had a severe allergic reaction to itolizumab or any ingredients in this product. Before starting treatment, patients must be screened for tuberculosis, and treatment should be used with caution in those with a history of recurrent infections or immunocompromised status. Vaccines should generally be avoided during therapy. Use during pregnancy or breastfeeding is not recommended due to insufficient safety data.